AI Engines For more Details: Perplexity Kagi Labs You
Cough Suppression: Cloperastine hydrochloride is used to alleviate cough symptoms associated with respiratory conditions such as the common cold, influenza, bronchitis, sinusitis, and allergies. It works by suppressing the cough reflex in the central nervous system, thereby reducing the frequency and intensity of coughing episodes. Cloperastine hydrochloride is particularly effective in managing non-productive or dry coughs, where there is no significant mucus production.
Antitussive Activity: Cloperastine hydrochloride acts centrally in the brain to inhibit the cough reflex, rather than directly affecting the respiratory tract. It exerts its antitussive effects by binding to sigma-1 receptors and blocking the transmission of cough signals along the cough reflex pathway. This mechanism of action distinguishes cloperastine hydrochloride from other cough suppressants, such as opioids or expectorants, which may have different modes of action or side effect profiles.
Efficacy: Cloperastine hydrochloride has been shown to be effective in reducing cough frequency and severity in clinical studies and trials involving patients with various respiratory conditions. It is often used as a symptomatic treatment to provide relief from bothersome cough symptoms while underlying respiratory infections or conditions resolve. Cloperastine hydrochloride may be used alone or in combination with other medications, depending on the nature and severity of the cough.
Safety and Tolerability: Cloperastine hydrochloride is generally well-tolerated by most individuals when used at recommended doses. Common side effects may include drowsiness, dizziness, headache, gastrointestinal upset (such as nausea or vomiting), dry mouth, and allergic reactions (such as skin rash or itching). These side effects are usually mild and transient, resolving with continued use or upon discontinuation of the medication. Serious adverse reactions to cloperastine hydrochloride are rare but may include hypersensitivity reactions or respiratory depression in susceptible individuals.
Dosage and Administration: Cloperastine hydrochloride is available in various oral formulations, including tablets, capsules, syrups, and lozenges, for administration according to the age and weight of the patient. The dosage and frequency of cloperastine hydrochloride therapy depend on factors such as the severity of cough symptoms, the patient's age and medical condition, and the specific formulation used. Patients should follow the instructions provided by their healthcare provider or medication label for proper dosing and administration.
Contraindications and Precautions: Cloperastine hydrochloride is contraindicated in individuals with known hypersensitivity to cloperastine or any of its components. It should be used with caution in patients with impaired renal or hepatic function, respiratory disorders (such as asthma or chronic obstructive pulmonary disease), or a history of substance abuse or addiction. Cloperastine hydrochloride may interact with other medications, particularly central nervous system depressants or monoamine oxidase inhibitors (MAOIs), increasing the risk of adverse effects or drug interactions.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Faecalibacterium prausnitzii | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Segatella bryantii | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
0 | 1 | Leyella stercorea | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
0 | 1 | Bacteroides humanifaecis | species | Decreases |
0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Flavonifractor plautii | species | Decreases |
0 | 1 | Hungatella hathewayi | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Prevotella intermedia | species | Decreases |
0 | 1 | Leyella lascolaii | species | Decreases |
0 | 1 | Paraprevotella clara | species | Decreases |
0 | 1 | Prevotella bivia | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Enterocloster clostridioformis | species | Decreases |
0 | 1 | Prevotella dentalis | species | Decreases |
0 | 1 | Blautia parvula | species | Decreases |
0 | 1 | Faecalibacterium prausnitzii | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
ADHD | 1.5 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.2 | 0.5 |
Allergic Rhinitis (Hay Fever) | 0.9 | 0.4 | 1.25 |
Allergies | 1.4 | 1.9 | -0.36 |
Allergy to milk products | 1 | 0.6 | 0.67 |
Alopecia (Hair Loss) | 0.7 | 0.7 | |
Alzheimer's disease | 3.2 | 3.9 | -0.22 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 0.6 | 2.5 |
Ankylosing spondylitis | 2.7 | 1 | 1.7 |
Anorexia Nervosa | 0.4 | 2.2 | -4.5 |
Antiphospholipid syndrome (APS) | 1 | 0.3 | 2.33 |
Asthma | 2.2 | 1.6 | 0.38 |
Atherosclerosis | 1.2 | 1 | 0.2 |
Atrial fibrillation | 2.2 | 2.1 | 0.05 |
Autism | 4.5 | 6.3 | -0.4 |
Autoimmune Disease | 0.1 | 0.2 | -1 |
Barrett esophagus cancer | 0.1 | -0.1 | |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 1 | 0.3 | 2.33 |
Brain Trauma | 0.2 | 0.7 | -2.5 |
Carcinoma | 1.1 | 0.7 | 0.57 |
Celiac Disease | 2.1 | 1.7 | 0.24 |
Cerebral Palsy | 0.7 | 0.6 | 0.17 |
Chronic Fatigue Syndrome | 1.9 | 3.3 | -0.74 |
Chronic Kidney Disease | 0.9 | 2.1 | -1.33 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.8 | -1 |
Chronic Urticaria (Hives) | 0.1 | 1.9 | -18 |
Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | 0 |
Cognitive Function | 0.8 | 0.4 | 1 |
Colorectal Cancer | 3.7 | 1.4 | 1.64 |
Constipation | 1.4 | 0.3 | 3.67 |
Coronary artery disease | 0.7 | 1.9 | -1.71 |
COVID-19 | 4 | 7 | -0.75 |
Crohn's Disease | 4.5 | 4.1 | 0.1 |
Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
cystic fibrosis | 0.6 | -0.6 | |
deep vein thrombosis | 0.9 | 0.7 | 0.29 |
Denture Wearers Oral Shifts | 0.3 | 0.3 | |
Depression | 5.5 | 4.4 | 0.25 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.4 | 0.9 | -1.25 |
Endometriosis | 0.9 | 0.7 | 0.29 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 1.5 | 1.6 | -0.07 |
erectile dysfunction | 0.3 | 0.3 | |
Fibromyalgia | 1.4 | 1.6 | -0.14 |
Functional constipation / chronic idiopathic constipation | 2.8 | 2.3 | 0.22 |
gallstone disease (gsd) | 1.1 | 0.5 | 1.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.6 | 1.17 |
Generalized anxiety disorder | 0.9 | 0.7 | 0.29 |
Glioblastoma | 0.1 | -0.1 | |
Gout | 1.1 | 0.3 | 2.67 |
Graves' disease | 0.6 | 0.9 | -0.5 |
Gulf War Syndrome | 0.1 | 1.9 | -18 |
Halitosis | 0.4 | 0.1 | 3 |
Hashimoto's thyroiditis | 1.5 | 1.5 | 0 |
Heart Failure | 1.5 | 1.3 | 0.15 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
High Histamine/low DAO | 0.2 | 0.2 | |
hypercholesterolemia (High Cholesterol) | 0.6 | -0.6 | |
hyperglycemia | 0.4 | 1.5 | -2.75 |
Hyperlipidemia (High Blood Fats) | 0.7 | 0.1 | 6 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.3 | 3 | -0.3 |
Hypothyroidism | 0.4 | 0 | 0 |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 0.7 | 2.9 | -3.14 |
Inflammatory Bowel Disease | 3.1 | 6.2 | -1 |
Insomnia | 0.7 | 2.3 | -2.29 |
Intelligence | 0.9 | 0.7 | 0.29 |
Intracranial aneurysms | 0.7 | 0.2 | 2.5 |
Irritable Bowel Syndrome | 2.7 | 3.7 | -0.37 |
ischemic stroke | 0.7 | 1 | -0.43 |
Liver Cirrhosis | 2.7 | 2 | 0.35 |
Long COVID | 4.3 | 3.7 | 0.16 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.3 | 0.7 | -1.33 |
Mast Cell Issues / mastitis | 0.1 | 0 | 0 |
ME/CFS with IBS | 0.6 | 0.5 | 0.2 |
ME/CFS without IBS | 0.3 | 0.9 | -2 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.1 | 0.5 | -4 |
Metabolic Syndrome | 3.3 | 4 | -0.21 |
Mood Disorders | 5.4 | 3.6 | 0.5 |
multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
Multiple Sclerosis | 2.7 | 4.1 | -0.52 |
Multiple system atrophy (MSA) | 0.8 | 0 | 0 |
myasthenia gravis | 0.1 | 0.2 | -1 |
neuropathic pain | 1.7 | -1.7 | |
Neuropathy (all types) | 0.4 | 0.6 | -0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 2.7 | -0.17 |
NonCeliac Gluten Sensitivity | 1 | 0.3 | 2.33 |
Obesity | 4.1 | 3.7 | 0.11 |
obsessive-compulsive disorder | 3 | 2.1 | 0.43 |
Osteoarthritis | 1.7 | 0.8 | 1.13 |
Osteoporosis | 0.6 | 1 | -0.67 |
pancreatic cancer | 0.1 | 0.1 | 0 |
Parkinson's Disease | 3.6 | 4.7 | -0.31 |
Polycystic ovary syndrome | 3.3 | 1.3 | 1.54 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0.1 | 0.2 | -1 |
primary biliary cholangitis | 0.1 | 0.8 | -7 |
Primary sclerosing cholangitis | 0.7 | 1.2 | -0.71 |
Psoriasis | 1.2 | 3.2 | -1.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 2 | 0.55 |
Rosacea | 0.1 | 0.3 | -2 |
Schizophrenia | 2.8 | 1.6 | 0.75 |
scoliosis | 0 | 0.9 | 0 |
Sjögren syndrome | 1.1 | 1.6 | -0.45 |
Sleep Apnea | 0 | 0.6 | 0 |
Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 1.1 | 1.6 | -0.45 |
Systemic Lupus Erythematosus | 1.8 | 1.1 | 0.64 |
Tic Disorder | 0.7 | 0.9 | -0.29 |
Tourette syndrome | 0.4 | 0.3 | 0.33 |
Type 1 Diabetes | 2.6 | 1.9 | 0.37 |
Type 2 Diabetes | 4.5 | 4.1 | 0.1 |
Ulcerative colitis | 2.9 | 4.9 | -0.69 |
Unhealthy Ageing | 2.8 | 1.4 | 1 |
Vitiligo | 1.8 | 0.5 | 2.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]